Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Standard Lithium Ltd (SLI) vs Smith & Nephew plc (SNN) Price & Performance

Standard Lithium LtdTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Standard Lithium Ltd vs Smith & Nephew plc — how do they compare? Standard Lithium Ltd trades at $2.37 (market cap $589.88M), while Smith & Nephew plc trades at $27.67 (market cap $11.63B). The key difference: Smith & Nephew plc is far larger — about 19.7× Standard Lithium Ltd's market cap, and Smith & Nephew plc pays a 2.85% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals.

SLISNN
Market Cap
$589.88M$11.63B
Sector
Basic MaterialsHealth
52-Week High
$5.65$38.53
52-Week Low
$1.93$27.80
Enterprise Value
$452.79M$14.66B
Dividend Yield
2.85%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Standard Lithium Ltd

Standard Lithium (SLI) trades at $2.40, down 0.83% today, with a bullish technical signal despite negative profitability metrics. The company shows progress with recent DOE clearance and key customer agreements, including LG Energy Solution, while maintaining 100% analyst buy ratings. Cash flow remains positive primarily from financing activities, though operational cash flow is negative as the company invests heavily in lithium project development.

The outlook hinges on successful project execution and Final Investment Decision for the Arkansas lithium project, which could unlock $250 million in government funding. Key risks include execution delays and negative profitability, but strong institutional interest and supportive government policies for critical minerals provide upside potential for patient investors.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.

Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.

Returns comparison

Trailing returns across standard periods

About Standard Lithium Ltd

Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.

Read more on SLI

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN